TheEdgeResearch
Home / Stocks / XVIPF

Xvivo Perfusion AB (publ) (XVIPF)

OTC Healthcare Medical - Devices
$19.15 ▲ +0.80%
Market Cap
$603.3M
Sector
Healthcare
Industry
Medical - Devices
Beta
1.46
52-Wk Range
17.4555-30.95
CEO
Christoffer Rosenblad
Country
SE
Currency
USD

Xvivo Perfusion AB (publ) operates in the Medical - Devices industry of the Healthcare sector, headquartered in Mölndal, VG, SE. The stock last traded at $19.15, up 0.80% on the session, giving a market capitalisation of $603.3M. On trailing twelve-month figures it carries a trailing P/E of 47.95, a net margin of 13.4%. Its beta of 1.46 implies it has historically moved more than the broad market.

Valuation & profitability (TTM)
P/E
47.95
Price / Sales
6.44
Price / Book
2.73
EV / EBITDA
27.95
Gross margin
64.1%
Operating margin
12.8%
Net margin
13.4%
Return on equity
—
Debt / equity
0.05
Current ratio
3.91
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
Other OTC
Employees
210
IPO date
2014-07-21
Headquarters
Mölndal, VG, SE
About Xvivo Perfusion AB (publ)

Xvivo Perfusion AB (publ) is a medical technology company that creates and supplies advanced solutions for the preservation and perfusion of organs, tissues, and cells, primarily for use in transplantation. The company's global reach extends across Sweden, the United States, both North and South America, Europe, the Middle East, Africa, and the Asia Pacific region. Its product line includes the XVIVO System (XPS), an integrated, ready-to-use cardiac bypass system designed to facilitate safe normothermic ex vivo lung perfusion (EVLP). To support this, the XPS Disposable Lung Kit offers all the necessary sterile, pre-packed components for EVLP procedures. Xvivo also provides STEEN Solution, an optimally formulated buffered extracellular solution specifically for perfusing isolated donor lungs during EVLP. Additional offerings comprise Perfadex Plus, an extracellular, low-potassium, dextran-based electrolyte preservation solution, and the XVIVO Silicone Tubing Set, used for efficient flushing of donor lungs during the procurement process. The company also manufactures the XVIVO LS and XVIVO Disposable Lung Set, both critical devices for EVLP. Furthermore, Xvivo provides the XVIVO Organ Chamber, a sterile, single-use disposable container for temporarily housing isolated lungs before transplantation, and the XVIVO Lung Cannula Set, another sterile, single-use disposable medical product. Established in 1998, Xvivo Perfusion AB (publ) is headquartered in Gothenburg, Sweden.

More research on XVIPF
XVIPF technical analysis XVIPF TheEdge Score Compare against peers
Open full interactive analysis & DCF →